Non-small cell lung cancer, colorectal cancer, and pancreatic cancer share many similarities: They cause innumerable deaths every year, have poor survival rates, and are a great burden on the entire healthcare system. However, they also happen to have one similarity that could potentially turn the tables: the KRAS gene. For decades, KRAS has been deemed as an un-targetable gene that plays a cardinal role in both the initiation and development of a plethora of cancers. This changed with recent breakthroughs targeting different KRAS inhibitors, spearheaded by some of our experts at PharmaLegacy. Download the brochure to learn more.